CREON Knowledge Challenge

2. Initial inflammatory pancreatic condition that may recur.
6. Digestive consequence resulting from inadequate pancreatic enzyme secretion.
7. Physician action encouraged to optimize therapy according to patient need.
10. Late symptom of severe pancreatic exocrine insufficiency.
11. Nutrient uptake deficiency improved with effective enzyme replacement.
12. Formulation concept allowing flexible dose adjustment by physicians.
16. Primary enzyme emphasized throughout the workshop for effective fat digestion.
17. Central disease state requiring pancreatic enzyme replacement therapy.
18. Comparator formulations shown to be inferior in key performance studies.
21. Severe pancreatic tissue damage associated with poor outcomes.
22. Built-in formulation feature protecting enzymes before intestinal release.

1. Standard therapy recommended for pancreatic exocrine insufficiency.
3. Supporting enzymatic activity improving fat digestion and symptom relief.
4. Key benefit achieved through acid protection and mini microspheres.
5. The only true formulation highlighted as ensuring complete drug delivery over claimed generic formulations.
8. Pathological process responsible for tissue injury in acute pancreatitis.
9. Site where CREON releases enzymes rapidly above pH 5.
13. High gastric pH resistance helping preserve enzyme activity.
14. Low moisture content contributing to improved formulation stability.
15. Progressive fibro-inflammatory form of pancreatitis.
19. Pancreatic function impaired in enzyme insufficiency.
20. Rapid process occurring in the duodenum to release pancreatic enzymes.